Nguyen H S, Milbach N, Hurrell S L, Cochran E, Connelly J, Bovi J A, Schultz C J, Mueller W M, Rand S D, Schmainda K M, LaViolette P S
From the Departments of Neurosurgery (H.S.N., W.M.M.).
Radiology (N.M., S.L.H., S.D.R., K.M.S., P.S.L.).
AJNR Am J Neuroradiol. 2016 Dec;37(12):2201-2208. doi: 10.3174/ajnr.A4898. Epub 2016 Aug 4.
Patients with recurrent glioblastoma often exhibit regions of diffusion restriction following the initiation of bevacizumab therapy. Studies suggest that these regions represent either diffusion-restricted necrosis or hypercellular tumor. This study explored postmortem brain specimens and a population analysis of overall survival to determine the identity and implications of such lesions.
Postmortem examinations were performed on 6 patients with recurrent glioblastoma on bevacizumab with progressively growing regions of diffusion restriction. ADC values were extracted from regions of both hypercellular tumor and necrosis. A receiver operating characteristic analysis was performed to define optimal ADC thresholds for differentiating tissue types. A retrospective population study was also performed comparing the overall survival of 64 patients with recurrent glioblastoma treated with bevacizumab. Patients were separated into 3 groups: no diffusion restriction, diffusion restriction that appeared and progressed within 5 months of bevacizumab initiation, and delayed or stable diffusion restriction. An additional analysis was performed assessing tumor O-methylguanine-DNA-methyltransferase methylation.
The optimal ADC threshold for differentiation of hypercellularity and necrosis was 0.736 × 10mm/s. Progressively expanding diffusion restriction was pathologically confirmed to be coagulative necrosis surrounded by viable tumor. Progressive lesions were associated with the worst overall survival, while stable lesions showed the greatest overall survival (P < .05). Of the 40% of patients with O-methylguanine-DNA-methyltransferase methylated tumors, none developed diffusion-restricted lesions.
Progressive diffusion-restricted lesions were pathologically confirmed to be coagulative necrosis surrounded by viable tumor and associated with decreased overall survival. Stable lesions were, however, associated with increased overall survival. All lesions were associated with O-methylguanine-DNA-methyltransferase unmethylated tumors.
复发性胶质母细胞瘤患者在开始使用贝伐单抗治疗后常出现弥散受限区域。研究表明,这些区域代表弥散受限性坏死或肿瘤细胞增多。本研究通过尸检脑标本及总生存的群体分析,以确定此类病变的性质及意义。
对6例接受贝伐单抗治疗的复发性胶质母细胞瘤患者进行尸检,这些患者存在逐渐扩大的弥散受限区域。从肿瘤细胞增多区域和坏死区域提取表观扩散系数(ADC)值。进行受试者工作特征分析以确定区分组织类型的最佳ADC阈值。还进行了一项回顾性群体研究,比较64例接受贝伐单抗治疗的复发性胶质母细胞瘤患者的总生存情况。患者被分为3组:无弥散受限、在贝伐单抗开始治疗后5个月内出现并进展的弥散受限、延迟或稳定的弥散受限。另外进行了一项分析,评估肿瘤O-甲基鸟嘌呤-DNA甲基转移酶的甲基化情况。
区分肿瘤细胞增多和坏死的最佳ADC阈值为0.736×10⁻³mm²/s。病理证实逐渐扩大的弥散受限为凝固性坏死,周围为存活肿瘤。进展性病变与最差的总生存相关,而稳定病变的总生存最佳(P<0.05)。在O-甲基鸟嘌呤-DNA甲基转移酶甲基化肿瘤患者中,40%均未出现弥散受限性病变。
病理证实进展性弥散受限性病变为凝固性坏死,周围为存活肿瘤,且与总生存降低相关。然而,稳定病变与总生存增加相关。所有病变均与O-甲基鸟嘌呤-DNA甲基转移酶未甲基化肿瘤相关。